Basic Information

Gene symbol CTAG1B Synonyms CTAG, ESO1, CT6.1, CTAG1, LAGE-2, LAGE2B, NY-ESO-1 Type of gene protein-coding
Description cancer/testis antigen 1B

GTO ID GTC0455
Trial ID NCT03709706
Disease Lung Non-Small Cell Carcinoma
Altered gene NY-ESO-1
Therapeutic/Target gene Target gene
TherapyTCR-T cell
Treatment Letetresgene autoleucel|GSK3377794|Lete-cel
HLAHLA-A*02:01|HLA-A*02:05|HLA-A*02:06
PhasePhase2
Recruitment statusActive, Not Recruiting
TitleA Phase 1b/2a Pilot Study to Evaluate the Safety and Tolerability of Autologous T-Cells Expressing Enhanced TCRs (T Cell Receptors) Specific for NY-ESO-1/LAGE-1a (GSK3377794) Alone, or in Combination With Pembrolizumab in HLA-A2+ Participants With NY-ESO-1- or LAGE-1a-Positive Advanced or Recurrent Non-Small Cell Lung Cancer
Year2018
CountryUnited States
Company sponsorGlaxoSmithKline
Other ID(s)208471

Clinical Result

Cohort1: Lete-cel
Administration route infusion
Donor type autologous
Pts 7
Age Adult, Older_Adult
Lymph depletion No
Adverse reactions 3/7(All-cause mortality); 5/7(Blood and lymphatic system disorders; Cardiac disorders; Gastrointestinal disorders; Immune system disorders; Infections and infestations; Nervous system disorders; Respiratory, thoracic and mediastinal disorders; Respiratory, thoracic and mediastinal disorders)
Cohort2: Lete-cel_Pembrolizumab
Administration route infusion
Donor type autologous
Pts 6
Age Adult, Older_Adult
Lymph depletion No
Adverse reactions 1/6(All-cause mortality); 4/6(Gastrointestinal disorders; General disorders; Immune system disorders; Infections and infestations; Injury, poisoning and procedural complications; Injury, poisoning and procedural complications; Renal and urinary disorders; Respiratory, thoracic and mediastinal disorders)

Relationship Graph

Overview of Knowledge Graph